Cidara Therapeutics Inc

Merck’s takeover of Cidara shows how a holding company can align post‑merger stakes, cut SEC reporting, and lock in a $221.50 cash payout—insights for investors, biotech funds and pharma players.

Merck’s final insider deal completes its takeover of Cidara Therapeutics—closing a cashless, $221.50‑per‑share merger that adds a promising anti‑infective pipeline and boosts investor confidence.